SNC112 / Shanghai Simnova Bio - LARVOL DELTA

Off-the-shelf BCMA/GPRC5D dual targeted CAR-NK cell therapy combined with Daratumumab in treating multiple myeloma (AACR 2025) - "B cell maturation antigen (BCMA), and Orphan G protein-coupled receptor, class C group 5-member D (GPRC5D) targeted chimeric antigen receptor (CAR) T cell therapies have been successful as treatment options for refractory/relapse multiple myeloma (RRMM) patients. However, only SNC112+DARA could achieve sustained tumor control against re-challenge tumor cells. Studies presented demonstrate the potential of SNC112+DARA combo as a highly effective multi-antigen targeting and a cost-effective off-the-shelf cell therapy in treating MM."

IO biomarker • Hematological Malignancies • Multiple Myeloma • Oncology • IL15